WO2023119232 - MITOCHONDRIAL ATP INHIBITORS TARGETING THE GAMMA SUBUNIT PREVENT METASTASIS
National phase entry is expected:
Publication Number
WO/2023/119232
Publication Date
29.06.2023
International Application No.
PCT/IB2022/062696
International Filing Date
22.12.2022
Title **
[English]
MITOCHONDRIAL ATP INHIBITORS TARGETING THE GAMMA SUBUNIT PREVENT METASTASIS
[French]
INHIBITEURS DE L’ATP MITOCHONDRIAL CIBLANT LA SOUS-UNITÉ GAMMA POUR PRÉVENIR UNE MÉTASTASE
Applicants **
LUNELLA BIOTECH, INC.
145 Richmond Road
Ottawa, Ontario K1Z 1A1, CA
Inventors
LISANTI, Michael P.
842 Wilmslow Road, Flat 27
Philip Godlee Lodge, Didsbury Village
Greater Manchester M20 2DS, GB
SOTGIA, Federica
842 Wilmslow Road, Flat 27
Philip Godlee Lodge, Didsbury Village
Greater Manchester M20 2DS, GB
FIORILLO, Marco
Apt. 127, Advent House 2/3, 1 Isaac Way
Manchester M4 7EE, GB
KANGASMETSA, Jussi
119 Clay Farm Drive
Cambridge CB2 9BX, GB
MAURO LIZCANO, Marta
117 Masson Place, 1 Hornbeam Way
Manchester M4 4AJ, GB
Priority Data
63/292,766
22.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CIPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1440 | |
| EPO | Filing, Examination | 7361 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 3910 |
Total: 13876 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
High ATP production by the mitochondrial ATP-synthase is a new therapeutic target for anti-cancer therapy, especially for preventing tumor progression. A mitochondrial-related gene signature for metastasis is described, which features the gamma-subunit of the mitochondrial ATP- synthase (ATP5F1C). Knock-down of ATP5F1C expression significantly reduces ATP- production, 3D anchorage-independent growth and cell migration. Administration of the Bedaquiline, or a Bedaquiline derivative with a TPP moiety, down-regulates ATP5F1C expression in vitro and prevents spontaneous metastasis in vivo. Mitochondrial ATP5F1C is a promising new biomarker and molecular target for future drug development, for the prevention of metastatic disease progression.[French]
Une production élevée d’ATP par l’ATP-synthase mitochondriale est une nouvelle cible thérapeutique pour une thérapie anticancéreuse, en particulier pour prévenir la progression d’une tumeur. L’invention décrit une signature génique associée aux mitochondries pour une métastase, qui comporte la sous-unité gamma de l’ATP-synthase mitochondriale (ATP5F1C). Une inactivation de l’expression de l’ATP5F1C réduit de manière significative la production de l’ATP, la croissance indépendante de l’ancrage 3D et la migration des cellules. L’administration de bédaquiline ou d’un dérivé de bédaquiline comportant une fraction de TPP provoque la régulation à la baisse in vitro de l’expression d’ATP5F1C et prévient une métastase spontanée in vivo. L’ATP5F1C mitochondrial est un nouveau biomarqueur prometteur et une cible moléculaire pour le développement de nouveaux médicaments, pour la prévention de la progression d’une maladie métastatique.